Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10298621 | 0.80 | PRKACA (0.41) | — | |
| SCHEMBL6895521 | 0.77 | HTR3A (0.38) | — | |
| SCHEMBL6895803 | 0.76 | IDO1 (0.32) | IRAK4IDO1TDO2 | |
| SCHEMBL6896441 | 0.76 | ALDH1A1 (0.33) | IRAK4LPLLIPGIDO1TDO2 | |
| SCHEMBL6893945 | 0.76 | HDAC1 (0.32) | — | |
| SCHEMBL6897422 | 0.75 | OPRM1 (0.33) | IRAK4IDO1TDO2 | |
| SCHEMBL6896299 | 0.75 | CYP11B2 (0.39) | IRAK4 | |
| SCHEMBL6895523 | 0.73 | HRH3 (0.39) | IRAK4 | |
| SCHEMBL10010702 | 0.73 | MAPT (0.55) | IRAK4LPLLIPGIDO1TDO2 | |
| SCHEMBL17678111 | 0.73 | KDM4E (0.52) | IRAK4IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172350-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | HRH3, HRH4, HRH2 | IRAK4 2383/4885LPL 3370/4885LIPG 2843/4885 |
| US-20120172350-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | IRAK4 2383/4885LPL 3370/4885LIPG 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.